Hydrolysis of leucine enkephalin in the nasal cavity of the rat--a possible factor in the low bioavailability of nasally administered peptides.
In order to investigate the utility of intranasal administration of peptides for systemic medication, the nasal absorption of the model peptide, leucine enkephalin (Tyr-Gly-Gly-Phe-Leu), was studied in the rat. At a concentration of 60 micrograms/ml in Ringer's buffer the pentapeptide was found to undergo, extensive hydrolysis in the nasal cavity. The hydrolysis rather than the polarity of the pentapeptide appears responsible for limiting the nasal absorption of this model compound. In the presence of dipeptides, the hydrolysis of leucine enkephalin was significantly inhibited. These results suggest that the nasal administration of peptides may become an important route for drug administration provided that the peptidases in the nasal mucosa can be transiently inhibited via coadministration of pharmacologically inactive peptidase substrates.
D000042:Absorption; D000281:Administration, Intranasal; D000818:Animals; D001682:Biological Availability; D004743:Enkephalin, Leucine / Q000008:administration & dosage / Q000378:metabolism*; D006868:Hydrolysis; D007700:Kinetics; D008297:Male; D009297:Nasal Mucosa / Q000378:metabolism*; D010455:Peptides / Q000008:administration & dosage / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains
D010455:Peptides; D004743:Enkephalin, Leucine